These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. Janin M; Mylonas E; Saada V; Micol JB; Renneville A; Quivoron C; Koscielny S; Scourzic L; Forget S; Pautas C; Caillot D; Preudhomme C; Dombret H; Berthon C; Barouki R; Rabier D; Auger N; Griscelli F; Chachaty E; Leclercq E; Courtier MH; Bennaceur-Griscelli A; Solary E; Bernard OA; Penard-Lacronique V; Ottolenghi C; de Botton S J Clin Oncol; 2014 Feb; 32(4):297-305. PubMed ID: 24344214 [TBL] [Abstract][Full Text] [Related]
3. Isocitrate dehydrogenase 1 mutations prime the all-trans retinoic acid myeloid differentiation pathway in acute myeloid leukemia. Boutzen H; Saland E; Larrue C; de Toni F; Gales L; Castelli FA; Cathebas M; Zaghdoudi S; Stuani L; Kaoma T; Riscal R; Yang G; Hirsch P; David M; De Mas-Mansat V; Delabesse E; Vallar L; Delhommeau F; Jouanin I; Ouerfelli O; Le Cam L; Linares LK; Junot C; Portais JC; Vergez F; Récher C; Sarry JE J Exp Med; 2016 Apr; 213(4):483-97. PubMed ID: 26951332 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of IDH2R140 and IDH2R172 mutations in patients with acute myeloid leukemia: a systematic review and meta-analysis. Qin Y; Shen K; Liu T; Ma H BMC Cancer; 2023 Jun; 23(1):527. PubMed ID: 37291515 [TBL] [Abstract][Full Text] [Related]
5. Isocitrate dehydrogenase (IDH) inhibition as treatment of myeloid malignancies: Progress and future directions. Upadhyay VA; Brunner AM; Fathi AT Pharmacol Ther; 2017 Sep; 177():123-128. PubMed ID: 28315358 [TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China. Wang JH; Chen WL; Li JM; Wu SF; Chen TL; Zhu YM; Zhang WN; Li Y; Qiu YP; Zhao AH; Mi JQ; Jin J; Wang YG; Ma QL; Huang H; Wu DP; Wang QR; Li Y; Yan XJ; Yan JS; Li JY; Wang S; Huang XJ; Wang BS; Jia W; Shen Y; Chen Z; Chen SJ Proc Natl Acad Sci U S A; 2013 Oct; 110(42):17017-22. PubMed ID: 24082129 [TBL] [Abstract][Full Text] [Related]
8. Recent advances of IDH1 mutant inhibitor in cancer therapy. Tian W; Zhang W; Wang Y; Jin R; Wang Y; Guo H; Tang Y; Yao X Front Pharmacol; 2022; 13():982424. PubMed ID: 36091829 [TBL] [Abstract][Full Text] [Related]
9. Biochemical, Epigenetic, and Metabolic Approaches to Target IDH Mutations in Acute Myeloid Leukemia. Fathi AT; Wander SA; Faramand R; Emadi A Semin Hematol; 2015 Jul; 52(3):165-71. PubMed ID: 26111463 [TBL] [Abstract][Full Text] [Related]
10. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. Mondesir J; Willekens C; Touat M; de Botton S J Blood Med; 2016; 7():171-80. PubMed ID: 27621679 [TBL] [Abstract][Full Text] [Related]
11. Reductive TCA cycle catalyzed by wild-type IDH2 promotes acute myeloid leukemia and is a metabolic vulnerability for potential targeted therapy. Zeng P; Lu W; Tian J; Qiao S; Li J; Glorieux C; Wen S; Zhang H; Li Y; Huang P J Hematol Oncol; 2022 Mar; 15(1):30. PubMed ID: 35313945 [TBL] [Abstract][Full Text] [Related]
13. IDH2 and NPM1 Mutations Cooperate to Activate Hoxa9/Meis1 and Hypoxia Pathways in Acute Myeloid Leukemia. Ogawara Y; Katsumoto T; Aikawa Y; Shima Y; Kagiyama Y; Soga T; Matsunaga H; Seki T; Araki K; Kitabayashi I Cancer Res; 2015 May; 75(10):2005-16. PubMed ID: 25795706 [TBL] [Abstract][Full Text] [Related]
14. Ivosidenib to treat adult patients with relapsed or refractory acute myeloid leukemia. Pasquier F; Lecuit M; Broutin S; Saada S; Jeanson A; Penard-Lacronique V; de Botton S Drugs Today (Barc); 2020 Jan; 56(1):21-32. PubMed ID: 32055803 [TBL] [Abstract][Full Text] [Related]
15. The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches. Gruber E; Kats LM Biochem Soc Trans; 2023 Aug; 51(4):1675-1686. PubMed ID: 37526143 [TBL] [Abstract][Full Text] [Related]
16. Detection Of Mutations In The Isocitrate Dehydrogenase Genes (IDH1/IDH2) Using castPCR Olarte I; García A; Ramos C; Arratia B; Centeno F; Paredes J; Rozen E; Kassack J; Collazo J; Martínez A Onco Targets Ther; 2019; 12():8023-8031. PubMed ID: 31632056 [TBL] [Abstract][Full Text] [Related]
17. Metabolic syndromes and malignant transformation: where the twain shall meet. Bhagwat N; Levine RL Sci Transl Med; 2010 Oct; 2(54):54ps50. PubMed ID: 20962328 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and Safety Profile of Ivosidenib in the Management of Patients with Acute Myeloid Leukemia (AML): An Update on the Emerging Evidence. Stemer G; Rowe JM; Ofran Y Blood Lymphat Cancer; 2021; 11():41-54. PubMed ID: 34188585 [TBL] [Abstract][Full Text] [Related]
19. Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma. van Lith SA; Navis AC; Lenting K; Verrijp K; Schepens JT; Hendriks WJ; Schubert NA; Venselaar H; Wevers RA; van Rooij A; Wesseling P; Molenaar RJ; van Noorden CJ; Pusch S; Tops B; Leenders WP Sci Rep; 2016 Jul; 6():30486. PubMed ID: 27460417 [TBL] [Abstract][Full Text] [Related]